EU grants conditional approval for Remdesivir - page 1

The active substance remdesivir has received conditional approval in the European Union for the treatment of severe Covid-19 diseases. The EU Commission announced this.

The Brussels authority relies on a corresponding recommendation from the European Medicines Agency (EMA). According to this, patients can be treated with it - if they are older than twelve years old, have pneumonia and need additional oxygen.

Remdesivir is one of the few effective remedies for the coronavirus-induced lung disease Covid-19. Studies have shown that hospitalization can be reduced by a few days.

The US government announced an agreement with manufacturer Gilead Sciences earlier this week that it would have purchased almost all of the drug's production for the next few months. However, Germany, for example, has already built up stocks. The EU Commission is also negotiating with the manufacturer to secure sufficient quantities of the active ingredient.